Barclays Maintains Overweight on Hims & Hers Health, Raises Price Target to $39

Benzinga Newsdesk www.benzinga.com Positive 54.6%

Neg 0% Neu 0% Pos 54.6%

Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and raises the price target from $29 to $39.